RxDoctor Payments Data

Joseph Vaughan, MD

Neurology · Knoxville, TNNPI 1700873627

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $156,225 of the $176,649 with a category attached, or 88.4%. Amgen accounts for 70.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $111,042 and has fallen 100.0% since, to $22 in 2025. Among neurology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$176,649in general payments, 2019–2025

Across 207 payments — averaging $853.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$124K
  • Lilly USA, LLC$52K
  • Kowa Pharmaceuticals America, Inc.$520
  • Boston Scientific$99
  • GE HealthCare$22
  • AbbVie$13
$2,500in research payments, 2019–2025

Across 1 payment — averaging $2500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Avanir Pharmaceuticals, Inc.$3K

What the payments were for

  • Consulting fees$3,5632%
  • Speaking & faculty fees$156,22588%
  • Travel & lodging$12,7517%
  • Food & beverage$4,0612%
  • Education$500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$176,649 in reported general payments places this provider in the 95th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$65,136
Medicare patients
171
Services billed
801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe59$51,144
NeuproRotigotine20$15,913
UbrelvyUbrogepant13$13,743
Gabapentin73$2,036
Duloxetine Hcl55$1,779
Oxcarbazepine19$1,313
Tizanidine Hcl59$1,269
Topiramate32$1,142
Carbidopa-LevodopaCarbidopa/Levodopa22$721
Primidone19$494
Levetiracetam14$480
Divalproex Sodium18$417
Memantine Hcl19$404
Doxepin Hcl14$301
Meloxicam52$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$13$13,74313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 361 neurology providers in Tennessee.

Other neurology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →